natgillin/translations-raw huggingface dataset:
In vitro studies in human liver microsomes indicate that tigecycline does not inhibit metabolism mediated by any of the following 6 cytochrome P450 (CYP) isoforms: 1A2, 2C8, 2C9, 2C19, 2D6, and 3A4 by competitive inhibition. 
In vitro ispitivanja s ljudskim jetrenim mikrosomima upućuju na to da tigeciklin ne inhibira metabolizam posredovan bilo kojim od slijedećih 6 izooblika citokroma P450 (CYP): 1A2, 2C8, 2C9, 2C19, 2D6 i 3A4 kompetitivnom inhibicijom.
Glucuronidation and renal excretion of unchanged tigecycline are secondary routes. 
Glukuronidacija i izlučivanje nepromijenjenog tigeciklina putem bubrega predstavljaju sekundarne puteve.
In an open-label, single ascending dose PK study, the safety of tigecycline was investigated in 25 children aged 8 to 16 years who recently recovered from infections. 
U otvorenom farmakokinetičkom ispitivanju s jednom postupno rastućom dozom sigurnost tigeciklina ispitivana je u 25 djece u dobi od 8 do 16 godina koja su se nedavno oporavila od infekcija.
Clinical experience in the use of tigecycline for the treatment of infections in paediatric patients aged 8 years and older is very limited (see sections 4.8 and 5.1). 
Kliničko iskustvo s upotrebom tigeciklina za liječenje infekcija u pedijatrijskih bolesnika u dobi od 8 godina i starijih vrlo je ograničeno (vidjeti dijelove 4.8 i 5.1).
Tigecycline is not extensively metabolised. 
Metabolizam tigeciklina nije opsežan.
If pancreatitis develops, treatment with tigecycline should be discontinued. 
Ako dođe do pankreatitisa, liječenje tigeciklinom mora se prekinuti.
Tigecycline is able to overcome the two major tetracycline resistance mechanisms, ribosomal protection and efflux. 
Tigeciklin može nadvladati dva glavna mehanizma rezistencije kod tetraciklina, ribosomsku zaštitu i efluks.
Race There were no differences in the clearance of tigecycline based on race. 
Rasa Nema razlika u klirensu tigeciklina koje se temelje na rasi.
Significant differences in sepsis/septic shock with tigecycline (2.2 %) vs comparators (1.1 %) were observed. 
Opažena je značajna razlika u sepsi/septičkom šoku s tigeciklinom (2,2 %) u odnosu na usporedne lijekove (1,1 %).
The single dose pharmacokinetic disposition of tigecycline was not altered in patients with renal insufficiency (creatinine clearance 30 ml/min, n=6). 
Farmakokinetička raspoloživost tigeciklina nakon jednokratnog doziranja nije bila promijenjena u bolesnika sa insuficijencijom bubrega (klirens kreatinina<30 ml/min, n=6).
• Low platelet levels in the blood(which may lead to an increased bleeding tendency and bruising/haematoma) 
• Niska razina krvnih pločica u krvi (koja može dovesti do povećane sklonosti krvarenju i modricama/hematomima)
In vitro, tigecycline is neither a competitive inhibitor nor an irreversible inhibitor of CYP450 enzymes (see section 5.2). 
Tigeciklin nije niti kompetitivni niti ireverzibilni inhibitor enzima CYP450 in vitro (vidjeti dio 5.2).
thrombocytopenia, increased international normalised ratio (INR) 
trombocitopenija, povećan međunarodni normalizirani omjer (INR)
Biliary excretion accounts for approximately 50 % of the total tigecycline excretion. 
Izlučivanje putem žuči odgovorno je za oko 50% ukupnog izlučivanja tigeciklina.
Inherently resistant organisms 
Prirođeno rezistentni organizmi
In general, tigecycline is considered bacteriostatic. 
Općenito se tigeciklin smatra bakteriostatskim antibiotikom.
For IV use only 
Samo za i.v. primjenu
Overall, the primary route of elimination for tigecycline is biliary excretion of unchanged tigecycline. 
Općenito, primarni put eliminacije tigeciklina jest izlučivanje nepromijenjenog tigeciklina putem žuči.
C-labelled tigecycline indicate that tigecycline is excreted readily via the milk of lactating rats. 
C-označen tigeciklin upućuju na to da se tigeciklin brzo izlučuje putem mlijeka štakorica tijekom laktacije.
Available pharmacodynamic/toxicological data in animals have shown excretion of tigecycline/metabolites in milk (see section 5.3). 
Dostupni farmakodinamički/toksikološki podaci u životinja pokazuju da se tigeciklin/metaboliti izlučuju u mlijeko (za detalje vidjeti 5.3).
Overgrowth of non-susceptible organisms, including fungi (see section 4.4). 
Prekomjerni rast neosjetljivih mikroorganizama, uključujući gljivice (vidjeti dio 4.4).
The recovery of the total radioactivity in faeces and urine following administration of 
Ukupna radioaktivnost koju je moguće pronaći u stolici i urinu nakon primjene
Once the powder has been made into a solution and diluted ready for use, it should be given to you immediately. 
Nakon što se prašak otopi i pripremljena otopina razrijedi, spremna je za primjenu i potrebno ju se odmah primijeniti.
Limited experience is also available in treating patients with concurrent bacteraemia (5.6 %). 
Također postoji ograničeno iskustvo u liječenju bolesnika s istovremenom bakterijemijom (5,6%).
Metabolism and nutrition disorders hypoglycaemia, hypoproteinaemia 
Poremećaji metabolizma i prehrane hipoglikemija, hipoproteinemija
Elderly No dosage adjustment is necessary in elderly patients (see section 5.2). 
Nije potrebna prilagodba doze u starijih bolesnika (vidjeti dio 5.2).
Tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections (see sections 4.4 and 5.1): 
Tygacil je indiciran u odraslih i u djece starije od osam godina za liječenje sljedećih infekcija (vidjeti dijelove 4.4 i 5.1):
The use of tigecycline may result in overgrowth of non-susceptible organisms, including fungi. 
Primjena tigeciklina može dovesti do pretjeranog rasta organizama koji nisu osjetljivi na ovaj lijek, uključujući gljivice.
There were a limited number of patients with severe underlying disease such as immunocompromised patients, patients with APACHE II scores  15 (3.3 %), or with surgically apparent multiple intra-abdominal abscesses (11.4 %). 
Uključen je ograničen broj bolesnika s teškom osnovnom bolešću, poput imunokompromitiranih bolesnika, bolesnika s APACHE II bodovima > 15 (3,3%) ili kirurški verificiranim višestrukim intraabdominalnim apscesima (11,4%).
Read the package leaflet before use for directions on reconstitution and dilution. 
Prije uporabe pročitati Uputu o lijeku za smjernice oko pripreme i razrjeđivanja.
In clinical trials, the most common medicinal product-related treatment emergent adverse reactions were reversible nausea (21 %) and vomiting (13 %), which usually occurred early (on treatment days 1-2) and were generally mild or moderate in severity. 
U kliničkim ispitivanjima najčešće nuspojave povezane s lijekom bile su mučnina (21%) i povraćanje (13%), koje su se obično javljale rano (1.- 2. dan liječenja) i općenito su bile blage do umjereno teške.
After reconstitution, 1 ml contains 10 mg of tigecycline. 
Nakon pripreme, 1 ml sadrži 10 mg tigeciklina.
Experience in the use of tigecycline for treatment of infections in patients with severe underlying diseases is limited. 
Iskustvo s primjenom tigeciklina u liječenju infekcija u bolesnika s teškim osnovnim bolestima je ograničeno.
Thus, 5 ml of reconstituted solution is equivalent to 50 mg of the active substance. 
Stoga 5 ml pripremljene otopine odgovara 50 mg djelatne tvari.
If this were the case, your doctor will monitor you closely. 
U tom će Vas slučaju liječnik češće kontrolirati.
• Complicated infection of the skin and soft tissues (the tissue below the skin), excluding diabetic foot infections. 
• Kompliciranu infekciju kože i mekih tkiva (tkiva ispod kože), ne uključujući infekcije dijabetičkog stopala
• Increases in liver enzymes, hyperbilirubinaemia (excess of bile pigment in the blood) 
• Porast jetrenih enzima, hiperbilirubinemija (višak žučnog pigmenta u krvi)
Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows: 
Europska komisija za ispitivanje osjetljivosti na antimikrobne lijekove (EUCAST, European Committee on Antimicrobial Susceptibility Testing) utvrdila je sljedeće granične vrijednosti minimalne inhibicijske koncentracije (MIK):
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 
POSEBNE MJERE ZA ZBRINJAVANJE E NEISKORIŠTENOG LIJEKA ILI OTPADNIH MATERIJALA KOJI POTJEČU
The steady-state AUC0-12h was 2349±850 ng•h/ml. 
AUC0-12h u stanju dinamičke ravnoteže iznosio je 2349±850 ng•h/ml.
If you are concerned that you may have been given too much Tygacil, talk to your doctor or nurse immediately. 
Ako Vas brine to da ste možda primili previše Tygacila, odmah razgovarajte s Vašim liječnikom ili medicinskom sestrom.
C-labelled material recovered in urine and faeces, but a glucuronide, an N-acetyl metabolite and a tigecycline epimer were also present. 
C-označenog materijala koji se mogao naći u urinu i stolici, ali bili su prisutni i glukuronid, N-acetilski metabolit, kao i epimer tigeciklina.
In clinical trials in cIAI, the most common type of infection in tigecycline-treated patients was complicated appendicitis (50.3 %), followed by other diagnoses less commonly reported such as complicated cholecystitis (9.6 %), perforation of intestine (9.6 %), intra-abdominal abscess (8.7 %), gastric or duodenal ulcer perforation (8.3 %), peritonitis (6.2 %) and complicated diverticulitis (6.0 %). 
U kliničkim ispitivanjima s cIAI-ovima (engl. complicated intra-abdominal infections), najčešći oblik infekcije u bolesnika koji su liječeni tigeciklinom bio je komplicirani apendicitis (50,3%), a potom slijede ostale rjeđe prijavljene dijagnoze poput kompliciranog kolecistitisa (9,6%), perforacija crijeva (9,6%), intraabdominalnog apscesa (8,7%), perforacije želučanog ili duodenalnog ulkusa (8,3%), peritonitis (6,2%) i komplicirani divertikulitis (6,0%).
Children and adolescents (8 to 17 years of age) Tigecycline is only to be used to treat patients aged 8 years and older after consultation with a physician with appropriate experience in the management of infectious diseases. 
Tigeciklin se smije upotrebljavati za liječenje bolesnika u dobi od 8 godina i starijih samo nakon savjetovanja s liječnikom koji ima odgovarajuće iskustvo u liječenju infektivnih bolesti.
The reconstituted solution should be yellow to orange in colour; if not, the solution should be discarded. 
Pripremljena otopina trebala bi biti žute do narančaste boje; ukoliko to nije slučaj, otopinu treba odbaciti.
In in vitro studies, no antagonism has been observed between tigecycline and other commonly used antibiotic classes. 
U in vitro ispitivanjima nije opažen antagonizam između tigeciklina i ostalih često primjenjivanih skupina antibiotika.
Do not take any diarrhoea medicine without first checking with your doctor. 
Nemojte uzimati lijekove protiv proljeva prije nego što se posavjetujete s Vašim liječnikom.
Results of animal studies indicate that tigecycline crosses the placenta and is found in foetal tissues. 
Rezultati ispitivanja na životinjama upućuju na to da tigeciklin prolazi kroz posteljicu i može se naći u fetalnim tkivima.
The following active substances should not be administered simultaneously through the same Y-site as tigecycline: Amphotericin B, amphotericin B lipid complex, diazepam, esomeprazole, omeprazole and intravenous solutions that could result in an increase of pH above 7. 
Slijedeće djelatne tvari ne smiju se primjenjivati kroz istu infuzijsku Y-liniju istovremeno s tigeciklinom: amfotericin B, amfotericin B lipidni kompleks, diazepam, esomeprazol, omeprazol i intravenske otopine koje mogu povisiti pH iznad 7.
Limited experience is also available in treating patients with concurrent bacteraemia (3.4 %). 
Također postoji samo ograničeno iskustvo u liječenju bolesnika s istovremenom bakterijemijom (3,4%).
Patients with severe underlying disease, such as those that were immunocompromised, patients with decubitus ulcer infections, or patients that had infections requiring longer than 14 days of treatment (for example, necrotizing fasciitis), were not enrolled. 
U ispitivanja nisu bili uključeni bolesnici s teškom osnovnom bolešću, poput onih koji su imunokompromitirani, zatim bolesnici s infekcijama dekubitalnog ulkusa ili bolesnici s infekcijom koja je zahtijevala više od 14 dana liječenja (primjerice, nekrotizirajući fasciitis).
Based on an in vitro study tigecycline is a P-gp substrate. 
Na temelju in vitro studija tigeciklin je P-gp supstrat.
A dosing regimen of 1.2 mg/kg of tigecycline every 12 hours (to a maximum dose of 50 mg every 12 hours) for children aged 8 to <12 years and of 50 mg every 12 hours for adolescents aged 12 to <18 years would likely result in exposures comparable to those observed in adults treated with the approved dosing regimen. 
Režim doziranja od 1,2 mg/kg tigeciklina svakih 12 sati (do maksimalne doze od 50 mg svakih 12 sati) za djecu u dobi od 8 do <12 i od 50 mg svakih 12 sati za adolescente u dobi od 12 do <18 najvjerojatnije će rezultirati izloženostima usporedivim s uočenima u odraslih liječenih odobrenim režimom doza.
Glycylcycline class antibiotics are structurally similar to tetracycline class antibiotics. 
Glicilciklinski razred antibiotika je strukturno sličan tetraciklinskom razredu antibiotika.
Tigecycline should be preferably administered over a 60-minute length of infusion in paediatric patients. 
Tigeciklin treba po mogućnosti primjenjivati u infuziji trajanja 60 minuta u pedijatrijskih bolesnika.
However, since tigecycline may prolong both prothrombin time (PT) and activated partial thromboplastin time (aPTT), the relevant coagulation tests should be closely monitored when tigecycline is co-administered with anticoagulants (see section 4.4). 
Međutim, budući da tigeciklin može produžiti kako protrombinsko vrijeme (PV), tako i aktivirano parcijalno tromboplastinsko vrijeme (APTV), potrebna je česta kontrola relevantnih koagulacijskih testova u slučaju istovremene primjene tigeciklina i antikoagulansa (vidjeti dio 4.4).
What Tygacil looks like and contents of the pack Tygacil is supplied as a powder for solution for infusion in a vial and looks like an orange powder or cake before it is diluted. 
Tygacil je dostupan kao prašak za otopinu za infuziju u bočici i prije razrjeđivanja izgleda kao narančasti prašak ili kolačić.
When administered through a Y-site, compatibility of tigecycline diluted in sodium chloride 0.9 % for injection is demonstrated with the following medicinal products or diluents: amikacin, dobutamine, dopamine HCl, gentamicin, haloperidol, Lactated Ringer's, lidocaine HCl, metoclopramide, morphine, norepinephrine, piperacillin/tazobactam (EDTA formulation), potassium chloride, propofol, ranitidine HCl, theophylline, and tobramycin. 
U slučaju primjene kroz Y-liniju, dokazana je kompatibilnost tigeciklina razrijeđenog u 0,9%-tnoj otopini natrijevog klorida sa slijedećim lijekovima ili otapalima: amikacin, dobutamin, dopaminklorid, gentamicin, haloperidol, Ringerova otopina s laktatom, lidokainklorid, metoklopramid, morfin, norepinefrin, piperacilin/tazobaktam (EDTA formulacija), kalijev klorid, propofol, ranitidinklorid, teofilin i tobramicin.
Therefore, clearance of tigecycline is not expected to be affected by active substances that inhibit or induce the activity of the CYP450 isoforms. 
Stoga se ne očekuje značajniji utjecaj djelatnih tvari koje inhibiraju ili induciraju aktivnost izoenzima CYP450 na klirens tigeciklina.
Digoxin did not affect the pharmacokinetic profile of tigecycline. 
Digoksin nije utjecao na farmakokinetički profil tigeciklina.
In clinical pharmacology studies using the therapeutic dosage regimen of 100 mg followed by 50 mg q12h, serum tigecycline steady-state Cmax was 866±233 ng/ml for 30-minute infusions and 634±97 ng/ml for 60-minute infusions. 
U kliničkim farmakološkim ispitivanjima u kojima je primjenjivana terapijska shema doziranja od 100 mg, nakon čega slijedi 50 mg svakih 12 sati, Cmax serumskog tigeciklina u stanju dinamičke ravnoteže iznosila je 866±233 ng/ml za 30-minutnu infuziju, odnosno 634±97 ng/ml za 60-minutne infuzije.
The adverse reaction profile of tigecycline in these 58 subjects was generally consistent with that in adults, with the exception of nausea (48.3 %), vomiting (46.6 %) and elevated lipase in serum (6.9 %) which were seen at greater frequencies in children than in adults. 
Profil nuspojava tigeciklina u tih 58 ispitanika općenito je bio dosljedna profilu odraslih, uz mučninu (48,3 %), povraćanje (46,6 %) i povećane lipaze u serumu (6,9 %) kao iznimke koje su učestalije primijećene u djece nego u odraslih.
C-tigecycline, radioactivity was well distributed to most tissues, with the highest overall exposure observed in bone marrow, salivary glands, thyroid gland, spleen, and kidney. 
C-tigeciklina, radioaktivnost se dobro distribuirala u većinu tkiva, pri čemu je najveća ukupna ekspozicija opažena u koštanoj srži, žlijezdama slinovnicama, štitnjači, slezeni i bubrezima.
Single dose 
Jedna doza
Decreased susceptibility in both groups has been attributed to the overexpression of the non-specific AcrAB multi-drug efflux pump. 
Smanjena osjetljivost u obje se skupine pripisuje pretjeranoj ekspresiji nespecifične AcrAB efluks pumpe za više lijekova.
Do not use this medicine after the expiry date which is stated on the vial. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na bočici.
The Tygacil solution should be yellow to orange in colour after dissolving; if it is not, the solution should be discarded. 
Otopina Tygacila nakon otapanja treba biti žute do narančaste boje; ukoliko to nije slučaj, otopinu treba baciti.
How to store Tygacil 
Kako primjenjivati Tygacil
Marketing Authorisation Holder Pfizer Europe MA EEIG Boulevard de la Plaine 17 1050 Bruxelles 
Nositelj odobrenja Pfizer Europe MA EEIG Boulevard de la Plaine 17 1050 Bruxelles Belgija
• Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections (see section 4.4); 
• Komplicirane infekcije kože i mekih tkiva, isključujući infekcije dijabetičkog stopala (vidjeti dio 4.4);
There are no or limited amount of data from the use of tigecycline in pregnant women. 
Nema podataka ili su podaci o primjeni tigeciklina u trudnica ograničeni.
Animal and human pharmacokinetic studies have demonstrated that tigecycline readily distributes to tissues. 
Farmakokinetička ispitivanja na životinjama i ljudima pokazale su da se tigeciklin brzo distribuira u tkiva.
Warfarin did not affect the pharmacokinetic profile of tigecycline. 
Varfarin nije utjecao na farmakokinetički profil tigeciklina.
• Abdominal pain, dyspepsia (stomach ache and indigestion), anorexia (loss of appetite) 
• Bol u trbuhu, dispepsija (bol u želucu i probavne smetnje), anoreksija (gubitak apetita)
A limited number of patients were enrolled with co-morbid factors such as diabetes (25.8 %), peripheral vascular disease (10.4 %), intravenous substance abuse (4.0 %), and HIVpositive infection (1.2 %). 
Uključen je ograničen broj bolesnika s istovremeno prisutnim bolestima poput šećerne bolesti (25,80%), periferne vaskularne bolesti (10,4%), ovisnika o intravenskim tvarima (4,0 %) te HIV-pozitivnom infekcijom (1,2%).
The vial should be gently swirled until the medicine is dissolved. 
Bočicu treba nježno vrtjeti sve dok se lijek ne otopi.
For intravenous use after reconstitution and dilution. 
Za primjenu u venu nakon pripreme i razrjeđivanja.
No loading dose was administered in these studies. 
U ovim ispitivanjima nije primijenjena udarna doza.
No dosage adjustment is necessary in patients with renal impairment or in patients undergoing haemodialysis (see section 5.2). 
Nije potrebna prilagodba doze u bolesnika s oštećenjem bubrega ili u bolesnika koji su na hemodijalizi (vidjeti dio 5.2).
Common side effects are (may affect up to 1 in 10 people): 
Česte nuspojave su (mogu se javiti u do 1 od 10 osoba):
As it is known for tetracycline class antibiotics, tigecycline may also induce permanent dental defects (discolouration and enamel defects) and a delay in ossification processes in foetuses, exposed in utero during the last half of gestation, and in children under eight years of age due to the enrichment in tissues with a high calcium turnover and formation of calcium chelate complexes (see section 4.4). 
Kao što je poznato za tetraciklinsku skupinu antibiotika, i tigeciklin može prouzročiti trajna oštećenja zuba (promjena boje i oštećenje cakline), usporiti proces osifikacije kod fetusa koji su bili in utero izloženi tijekom druge polovice trudnoće, kao i u djece mlađe od osam godina uslijed nakupljanja u tkivima s velikom pregradnjom kalcija i stvaranja kompleksa kelata kalcija (vidjeti dio 4.4).
Although hepatic failure may occur in patients treated with tigecycline due to the underlying conditions or concomitant medicinal products, a possible contribution of tigecycline should be considered (see section 4.8). 
Iako se zatajenje jetre može javiti u bolesnika liječenih tigeciklinom zbog drugih osnovnih bolesti ili istovremene primjene drugih lijekova, potrebno je razmotriti mogući doprinos tigeciklina (vidjeti dio 4.8).
In clinical studies in complicated skin and soft tissue infections (cSSTI), complicated intra-abdominal infections (cIAI), diabetic foot infections, nosocomial pneumonia and studies in resistant pathogens, a numerically higher mortality rate among tigecycline treated patients has been observed as compared to the comparator treatment. 
U kliničkim ispitivanjima s kompliciranim infekcijama kože i mekih tkiva, kompliciranim intraabdominalnim infekcijama, infekcijama dijabetičkog stopala, bolničkom pneumonijom i ispitivanjima rezistentnih patogena, opažena je brojčano veća stopa smrtnosti među bolesnicima koji su primali tigeciklin u odnosu na one koji su primali usporedni lijek.
Tygacil is distributed in a ten vial tray pack. 
Tygacil se isporučuje u pakovanju od deset bočica.
These may be symptoms of acute pancreatitis (inflamed pancreas which may result in severe abdominal pain, nausea, and vomiting). 
To mogu biti simptomi akutnog pankreatitisa (upale gušterače koja može dovesti do snažne boli u abdomenu, mučnine i povraćanja).
Tigecycline is vulnerable to chromosomally-encoded multi-drug efflux pumps of Proteeae and Pseudomonas aeruginosa. 
Tigeciklin je osjetljiv na kromosomski kodirane efluks pumpe za više lijekova u Proteeae i Pseudomonas aeruginosa.
In an open-label, ascending multiple-dose study, 39 children aged 8 to 11 years with cIAI or cSSTI were administered tigecycline (0.75, 1, or 1.25 mg/kg). 
U otvorenom ispitivanju s više postupno rastućih doza, 39 djece u dobi od 8 do 11 godina s cIAI or cSSTI dobili su tigeciklin (0,75, 1 ili 1,25 mg/kg).
Tygacil should not be used in children under 8 years of age due to the lack of safety and efficacy data in this age group and because tigecycline may be associated with permanent teeth discolouration (see sections 4.2 and 4.8). 
Tygacil se ne smije primjenjivati kod djece mlađe od 8 godina zbog nedostatka podataka o sigurnosti i djelotvornosti u toj dobnoj skupini i zato što tigeciklin može biti povezan s trajnom promjenom boje zuba(vidjeti dijelove 4.2 i 4.8).
Tigecycline should be preferably administered over a 60-minute length of infusion in paediatric patients (see section 4.4). 
Tigeciklin treba po mogućnosti primjenjivati u infuziji trajanja 60 minuta u pedijatrijskih bolesnika (vidjeti dio 4.4).
Patients hypersensitive to tetracycline class antibiotics may be hypersensitive to tigecycline. 
Bolesnici koji su preosjetljivi na tetraciklinsku skupinu antibiotika mogu biti preosjetljivi i na tigeciklin.
The other ingredients are lactose monohydrate, hydrochloric acid, and sodium hydroxide. 
Pomoćne tvari su laktoza hidrat, kloridna kiselina i natrijev hidroksid.
• Jaundice (yellow coloration of the skin), inflammation of the liver 
• Žutica (žutilo kože), upala jetre
Concomitant administration of tigecycline and warfarin (25 mg single-dose) to healthy subjects resulted in a decrease in clearance of R-warfarin and S-warfarin by 40 % and 23 %, and an increase in AUC by 68 % and 29 %, respectively. 
Istovremena primjena tigeciklina i varfarina (jednokratna doza od 25 mg) kod zdravih ispitanika dovela je do smanjenja klirensa R-varfarina za 40%, a S-varfarina za 23% te porasta AUC-a Rvarfarina za 68% odnosno S-varfarina za 29%.